CXCL13 Levels Are Elevated in Patients with Waldenström Macroglobulinemia, and Are Predictive of Major Response to Ibrutinib

Overview

Journal Haematologica

Specialty Hematology

Date 2017 Aug 12

PMID 28798070

Citations 14

Authors

Josephine M Vos

Nickolas Tsakmaklis

Christopher J Patterson

Kirsten Meid

Jorge J Castillo

Philip Brodsky

Tomas Ganz

Steven T Pals

Marie Jose Kersten

Lian Xu

Guang Yang

Steven P Treon

Zachary R Hunter

Affiliations

Soon will be listed here.

Citing Articles

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.

Treon S, Kotton C, Park D, Moranzoni G, Lemvigh C, Gathe Jr J Front Immunol. 2025; 15:1369619.

PMID: 39906744 PMC: 11791645. DOI: 10.3389/fimmu.2024.1369619.

Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia.

Chen J, Jia M, Cai H, Li Z, Li J, Zhou D Ann Hematol. 2024; 103(9):3667-3675.

PMID: 38448788 DOI: 10.1007/s00277-024-05690-3.

CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia.

Ahmed H, Nafady A, Ahmed E, Hassan E, Soliman W, Elbadry M Ann Hematol. 2023; 103(3):781-792.

PMID: 37946029 PMC: 10867040. DOI: 10.1007/s00277-023-05540-8.

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression.

Beider K, Voevoda-Dimenshtein V, Zoabi A, Rosenberg E, Magen H, Ostrovsky O J Hematol Oncol. 2022; 15(1):144.

PMID: 36217194 PMC: 9549634. DOI: 10.1186/s13045-022-01366-5.

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.

Castillo J, Sarosiek S, Gustine J, Flynn C, Leventoff C, White T Blood Adv. 2021; 6(3):1015-1024.

PMID: 34965304 PMC: 8945307. DOI: 10.1182/bloodadvances.2021006106.

References

Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning R . A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013; 122(7):1222-32. DOI: 10.1182/blood-2012-12-475111. View

Elsawa S, Novak A, Ziesmer S, Almada L, Hodge L, Grote D . Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood. 2011; 118(20):5540-9. PMC: 3217355. DOI: 10.1182/blood-2011-04-351742. View

de Rooij M, Kuil A, Kraan W, Kersten M, Treon S, Pals S . Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia. Haematologica. 2015; 101(3):e111-5. PMC: 4815740. DOI: 10.3324/haematol.2015.137265. View

Ho A, Hatjiharissi E, Ciccarelli B, Branagan A, Hunter Z, Leleu X . CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008; 112(12):4683-9. PMC: 2597134. DOI: 10.1182/blood-2007-04-084525. View

Xu L, Hunter Z, Tsakmaklis N, Cao Y, Yang G, Chen J . Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2015; 172(5):735-44. PMC: 5409813. DOI: 10.1111/bjh.13897. View

Hunter Z, Xu L, Yang G, Tsakmaklis N, Vos J, Liu X . Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016; 128(6):827-38. PMC: 4982454. DOI: 10.1182/blood-2016-03-708263. View

Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M . Immunoassay for human serum hepcidin. Blood. 2008; 112(10):4292-7. DOI: 10.1182/blood-2008-02-139915. View

Treon S, Xu L, Yang G, Zhou Y, Liu X, Cao Y . MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012; 367(9):826-33. DOI: 10.1056/NEJMoa1200710. View

Niemann C, Herman S, Maric I, Gomez-Rodriguez J, Biancotto A, Chang B . Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Clin Cancer Res. 2015; 22(7):1572-82. PMC: 4818677. DOI: 10.1158/1078-0432.CCR-15-1965. View

10.

Tripodo C, Gri G, Piccaluga P, Frossi B, Guarnotta C, Piconese S . Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010; 177(2):792-802. PMC: 2913370. DOI: 10.2353/ajpath.2010.091286. View

11.

de Rooij M, Kuil A, Geest C, Eldering E, Chang B, Buggy J . The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012; 119(11):2590-4. DOI: 10.1182/blood-2011-11-390989. View

12.

Treon S, Xu L, Hunter Z . MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med. 2015; 373(6):584-6. DOI: 10.1056/NEJMc1506192. View

13.

Ciccarelli B, Patterson C, Hunter Z, Hanzis C, Ioakimidis L, Manning R . Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011; 11(1):160-3. DOI: 10.3816/CLML.2011.n.038. View

14.

Treon S, Tripsas C, Meid K, Warren D, Varma G, Green R . Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015; 372(15):1430-40. DOI: 10.1056/NEJMoa1501548. View

15.

Owen R, Kyle R, Stone M, Rawstron A, Leblond V, Merlini G . Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2012; 160(2):171-6. DOI: 10.1111/bjh.12102. View